DCAF7 and neoplasm: DCAF7 is frequently activated by genetic and epigenetic mechanisms across cancers, associates with an immunotherapy‐relevant tumour immune milieu, and drives Wnt/β‐catenindependent malignant phenotypes in LIHC.